Revive Therapeutics Ltd. (RVVTF) 0.1310 $RVVTF
Revive Therapeutics Provides Clinical and Corporate Update
Marketwire Canada - Tue May 10, 6:02AM CDT
TORONTO, ONTARIO--(Marketwired - May 10, 2016) - Revive Therapeutics Ltd. ("Revive" or the "Company"
(TSX VENTURE:RVV)(OTCQB:RVVTF), a company focused on commercializing treatments for gout and rare diseases such as cystinuria, Wilson's disease and Rett syndrome, today provided an update on the progress of its clinical activities for its drug candidate, Bucillamine, for the treatment of gout and cystinuria, as well as its corporate initiatives.
RVV.VN: 0.165 (+0.005)
Revive Therapeutics Announces Results for the Three and Nine Months Ended March 31, 2016
Marketwired - Mon May 09, 7:02AM CDT
TORONTO, ONTARIO--(Marketwired - May 9, 2016) - Revive Therapeutics Ltd. ("Revive" or the "Company" (TSX VENTURE:RVV) (OTCQB:RVVTF), a company focused on commercializing treatments for gout and rare diseases such as cystinuria, Wilson's disease and Rett syndrome, announced today its results for the three and nine months ended March 31, 2016. The unaudited condensed interim consolidated financial statements and Management's Discussion and Analysis for the period may be viewed on SEDAR at www.sedar.com.
RVV.VN: 0.165 (+0.005)
Revive Therapeutics Appoints Tessio Rebello, Ph.D. as Clinical Advisor
Marketwired - Tue Apr 19, 3:01PM CDT
Revive Therapeutics Ltd. ("Revive" or the "Company" (TSX VENTURE: RVV)(OTCQB: RVVTF), a company focused on commercializing treatments for gout, and rare diseases such as Cystinuria, Wilson's disease and Rett Syndrome, today announced that Tessio Rebello, Ph.D., will join the Company as a clinical advisor for the Company.
RVV.VN: 0.165 (+0.005)
Revive Therapeutics Announces Issuance of U.S. Patent Related to Bucillamine in the Treatment of Gout
Marketwired - Wed Jan 20, 6:01AM CST
Revive Therapeutics Ltd. ("Revive" or the "Company" (TSX VENTURE: RVV)(OTCQB: RVVTF), a company focused on commercializing treatments for gout, and rare diseases such as Cystinuria, Wilson's disease and Rett syndrome, today announced the issuance of U.S. Patent 9,238,018, titled, 'The Use of Bucillamine in the Treatment of Gout', by the U.S. Patent and Trademark Office (USPTO). The term of the newly issued patent extends to November 2033.
RVV.VN: 0.165 (+0.005)
Revive Therapeutics to Present at Noble Capital Markets' Investor Conference
Marketwired - Tue Jan 19, 7:03AM CST
Revive Therapeutics Ltd. ("Revive" or the "Company" (OTCQB: RVVTF)(TSX VENTURE: RVV), a company focused on commercializing treatments for gout, and rare diseases such as Cystinuria, Wilson's disease and Rett syndrome, today announced that its Chief Executive Officer, Fabio Chianelli, will present at the NobleCon12 - Noble Financial Capital Markets' Twelfth Annual Investor Conference at Club Med in Sandpiper Bay, Florida, on Tuesday, January 19th at 4:30pm Eastern Standard Time.
RVV.VN: 0.165 (+0.005)
Revive Therapeutics Announces DTC Eligibility of Its Common Shares
Marketwired - Tue Dec 08, 3:01PM CST
Revive Therapeutics Ltd. ("Revive" or the "Company" (OTCQB: RVVTF)(TSX VENTURE: RVV), a company focused on commercializing treatments for gout, and rare diseases such as Cystinuria, Wilson's disease and Rett syndrome, today announced that the Depository Trust Company (DTC) has approved the Company's eligibility application for Revive Therapeutics Ltd. (CUSIP 761516103), effective December 7, 2015.
RVV.VN: 0.165 (+0.005)
Revive Therapeutics Retains the Ruth Group to Build U.S. Investment Community Awareness
Marketwired - Mon Dec 07, 6:01AM CST
Revive Therapeutics Ltd. ("Revive" or the "Company" (TSX VENTURE: RVV)(OTCQB: RVVTF), a company focused on commercializing treatments for gout, and rare diseases such as Cystinuria, Wilson's disease and Rett syndrome, today announced that it has retained The Ruth Group ("TRG", a New York City-based leading investor relations and financial communications agency dedicated to the healthcare industry. The Ruth Group (www.theruthgroup.com) will counsel management and execute on the development and implementation of a strategic investor relations program with the objective of increasing awareness of Revive with the investment community in the U.S.
JPM: 66.44 (+0.25), RVV.VN: 0.165 (+0.005)
Revive Therapeutics Announces Positive Final Results from Its Phase 2a Study for the Treatment of Acute Gout Flares
Marketwired - Tue Dec 01, 6:02AM CST
Revive Therapeutics Ltd. ("Revive" or the "Company" (TSX VENTURE: RVV) (OTCQB: RVVTF), a company focused on commercializing treatments for gout, and rare diseases such as Cystinuria, Wilson's disease and Rett syndrome, today announced positive final results from its phase 2a proof-of-concept clinical study of REV-002 (Bucillamine), an oral anti-inflammatory agent, for the treatment of acute gout flares.
RVV.VN: 0.165 (+0.005)
Revive Therapeutics Ltd. Announces Results for the Three Months Ended September 30, 2015
Marketwired - Thu Nov 26, 6:01PM CST
Revive Therapeutics Ltd. ("Revive" or the "Company" (TSX VENTURE: RVV)(OTCQB: RVVTF), a company focused on commercializing treatments for gout, and rare diseases such as Cystinuria, Wilson's disease and Rett syndrome, today announced its results for the three months ended September 30, 2015. The unaudited condensed interim consolidated financial statements and related management's discussion and analysis for the three months ended September 30, 2015 may be viewed on SEDAR at www.sedar.com.
RVV.VN: 0.165 (+0.005)
Revive Therapeutics Announces Listing on the OTCQB Market Exchange
Marketwire Canada - Wed Nov 25, 6:00AM CST
Revive Therapeutics Ltd. ("Revive" or the "Company" (TSX VENTURE:RVV)(OTCQB:RVVTF), a company focused on commercializing treatments for gout, and rare diseases such as Cystinuria, Wilson's disease and Rett syndrome, today announced that the Company's common shares have been listed for trading on the OTCQB(R) Market exchange in the United States under the symbol "RVVTF". The Company's common shares will continue to be traded on the Toronto TSX Venture Exchange under its existing symbol "RVV".
RVV.VN: 0.165 (+0.005)
Revive Therapeutics Provides Clinical and Corporate Update
Marketwire Canada - Tue May 10, 6:02AM CDT
TORONTO, ONTARIO--(Marketwired - May 10, 2016) - Revive Therapeutics Ltd. ("Revive" or the "Company"
(TSX VENTURE:RVV)(OTCQB:RVVTF), a company focused on commercializing treatments for gout and rare diseases such as cystinuria, Wilson's disease and Rett syndrome, today provided an update on the progress of its clinical activities for its drug candidate, Bucillamine, for the treatment of gout and cystinuria, as well as its corporate initiatives. RVV.VN: 0.165 (+0.005)
Revive Therapeutics Announces Results for the Three and Nine Months Ended March 31, 2016
Marketwired - Mon May 09, 7:02AM CDT
TORONTO, ONTARIO--(Marketwired - May 9, 2016) - Revive Therapeutics Ltd. ("Revive" or the "Company"
(TSX VENTURE:RVV) (OTCQB:RVVTF), a company focused on commercializing treatments for gout and rare diseases such as cystinuria, Wilson's disease and Rett syndrome, announced today its results for the three and nine months ended March 31, 2016. The unaudited condensed interim consolidated financial statements and Management's Discussion and Analysis for the period may be viewed on SEDAR at www.sedar.com. RVV.VN: 0.165 (+0.005)
Revive Therapeutics Appoints Tessio Rebello, Ph.D. as Clinical Advisor
Marketwired - Tue Apr 19, 3:01PM CDT
Revive Therapeutics Ltd. ("Revive" or the "Company"
(TSX VENTURE: RVV)(OTCQB: RVVTF), a company focused on commercializing treatments for gout, and rare diseases such as Cystinuria, Wilson's disease and Rett Syndrome, today announced that Tessio Rebello, Ph.D., will join the Company as a clinical advisor for the Company. RVV.VN: 0.165 (+0.005)
Revive Therapeutics Announces Issuance of U.S. Patent Related to Bucillamine in the Treatment of Gout
Marketwired - Wed Jan 20, 6:01AM CST
Revive Therapeutics Ltd. ("Revive" or the "Company"
(TSX VENTURE: RVV)(OTCQB: RVVTF), a company focused on commercializing treatments for gout, and rare diseases such as Cystinuria, Wilson's disease and Rett syndrome, today announced the issuance of U.S. Patent 9,238,018, titled, 'The Use of Bucillamine in the Treatment of Gout', by the U.S. Patent and Trademark Office (USPTO). The term of the newly issued patent extends to November 2033. RVV.VN: 0.165 (+0.005)
Revive Therapeutics to Present at Noble Capital Markets' Investor Conference
Marketwired - Tue Jan 19, 7:03AM CST
Revive Therapeutics Ltd. ("Revive" or the "Company"
(OTCQB: RVVTF)(TSX VENTURE: RVV), a company focused on commercializing treatments for gout, and rare diseases such as Cystinuria, Wilson's disease and Rett syndrome, today announced that its Chief Executive Officer, Fabio Chianelli, will present at the NobleCon12 - Noble Financial Capital Markets' Twelfth Annual Investor Conference at Club Med in Sandpiper Bay, Florida, on Tuesday, January 19th at 4:30pm Eastern Standard Time. RVV.VN: 0.165 (+0.005)
Revive Therapeutics Announces DTC Eligibility of Its Common Shares
Marketwired - Tue Dec 08, 3:01PM CST
Revive Therapeutics Ltd. ("Revive" or the "Company"
(OTCQB: RVVTF)(TSX VENTURE: RVV), a company focused on commercializing treatments for gout, and rare diseases such as Cystinuria, Wilson's disease and Rett syndrome, today announced that the Depository Trust Company (DTC) has approved the Company's eligibility application for Revive Therapeutics Ltd. (CUSIP 761516103), effective December 7, 2015. RVV.VN: 0.165 (+0.005)
Revive Therapeutics Retains the Ruth Group to Build U.S. Investment Community Awareness
Marketwired - Mon Dec 07, 6:01AM CST
Revive Therapeutics Ltd. ("Revive" or the "Company"
(TSX VENTURE: RVV)(OTCQB: RVVTF), a company focused on commercializing treatments for gout, and rare diseases such as Cystinuria, Wilson's disease and Rett syndrome, today announced that it has retained The Ruth Group ("TRG", a New York City-based leading investor relations and financial communications agency dedicated to the healthcare industry. The Ruth Group (www.theruthgroup.com) will counsel management and execute on the development and implementation of a strategic investor relations program with the objective of increasing awareness of Revive with the investment community in the U.S. JPM: 66.44 (+0.25), RVV.VN: 0.165 (+0.005)
Revive Therapeutics Announces Positive Final Results from Its Phase 2a Study for the Treatment of Acute Gout Flares
Marketwired - Tue Dec 01, 6:02AM CST
Revive Therapeutics Ltd. ("Revive" or the "Company"
(TSX VENTURE: RVV) (OTCQB: RVVTF), a company focused on commercializing treatments for gout, and rare diseases such as Cystinuria, Wilson's disease and Rett syndrome, today announced positive final results from its phase 2a proof-of-concept clinical study of REV-002 (Bucillamine), an oral anti-inflammatory agent, for the treatment of acute gout flares. RVV.VN: 0.165 (+0.005)
Revive Therapeutics Ltd. Announces Results for the Three Months Ended September 30, 2015
Marketwired - Thu Nov 26, 6:01PM CST
Revive Therapeutics Ltd. ("Revive" or the "Company"
(TSX VENTURE: RVV)(OTCQB: RVVTF), a company focused on commercializing treatments for gout, and rare diseases such as Cystinuria, Wilson's disease and Rett syndrome, today announced its results for the three months ended September 30, 2015. The unaudited condensed interim consolidated financial statements and related management's discussion and analysis for the three months ended September 30, 2015 may be viewed on SEDAR at www.sedar.com. RVV.VN: 0.165 (+0.005)
Revive Therapeutics Announces Listing on the OTCQB Market Exchange
Marketwire Canada - Wed Nov 25, 6:00AM CST
Revive Therapeutics Ltd. ("Revive" or the "Company"
(TSX VENTURE:RVV)(OTCQB:RVVTF), a company focused on commercializing treatments for gout, and rare diseases such as Cystinuria, Wilson's disease and Rett syndrome, today announced that the Company's common shares have been listed for trading on the OTCQB(R) Market exchange in the United States under the symbol "RVVTF". The Company's common shares will continue to be traded on the Toronto TSX Venture Exchange under its existing symbol "RVV". RVV.VN: 0.165 (+0.005)
